Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Suh M, Cheon G, Lee D,
Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,
Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,
Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,
Keywords: Neuroendocrine tumours, lanreotide,
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Minczeles N, van Eijck C, van Gils M, van Velthuysen M, Nieveen van Dijkum E,
Keywords: neoadjuvant, peptide receptor radionuclide therapy, neuroendocrine, pancreas, surgery,
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Teulé A, Alonso T, González E, De La Cruz G, Houchard A,
Keywords: NET, lanreotide, pancreas, study,